AVXL PE Ratio & Valuation,Is AVXL Overvalued

AVXL Relative Valuation

AVXL's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, AVXL is overvalued; if below, it's undervalued.

Historical Valuation

Anavex Life Sciences Corp (AVXL) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -15.65. The fair price of Anavex Life Sciences Corp (AVXL) is between -- to -- according to relative valuation methord.

Relative Value

Fair Zone

-----

Current Price：4.02

Fair

-8.37

0.51

EV/EBITDA

Anavex Life Sciences Corp. (AVXL) has a current EV/EBITDA of 0.51. The 5-year average EV/EBITDA is -4.48. The thresholds are as follows: Strongly Undervalued below -18.78, Undervalued between -18.78 and -11.63, Fairly Valued between 2.66 and -11.63, Overvalued between 2.66 and 9.81, and Strongly Overvalued above 9.81. The current Forward EV/EBITDA of 0.51 falls within the Historic Trend Line -Fairly Valued range.

-5.32

EV/EBIT

Anavex Life Sciences Corp. (AVXL) has a current EV/EBIT of -5.32. The 5-year average EV/EBIT is -12.35. The thresholds are as follows: Strongly Undervalued below -40.11, Undervalued between -40.11 and -26.23, Fairly Valued between 1.53 and -26.23, Overvalued between 1.53 and 15.41, and Strongly Overvalued above 15.41. The current Forward EV/EBIT of -5.32 falls within the Historic Trend Line -Fairly Valued range.

0.00

Anavex Life Sciences Corp. (AVXL) has a current PS of 0.00. The 5-year average PS is 145.97. The thresholds are as follows: Strongly Undervalued below -686.39, Undervalued between -686.39 and -270.21, Fairly Valued between 562.15 and -270.21, Overvalued between 562.15 and 978.32, and Strongly Overvalued above 978.32. The current Forward PS of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.38

P/OCF

Anavex Life Sciences Corp. (AVXL) has a current P/OCF of 0.38. The 5-year average P/OCF is -10.68. The thresholds are as follows: Strongly Undervalued below -34.98, Undervalued between -34.98 and -22.83, Fairly Valued between 1.47 and -22.83, Overvalued between 1.47 and 13.61, and Strongly Overvalued above 13.61. The current Forward P/OCF of 0.38 falls within the Historic Trend Line -Fairly Valued range.

0.66

P/FCF

Anavex Life Sciences Corp. (AVXL) has a current P/FCF of 0.66. The 5-year average P/FCF is -7.18. The thresholds are as follows: Strongly Undervalued below -24.89, Undervalued between -24.89 and -16.04, Fairly Valued between 1.68 and -16.04, Overvalued between 1.68 and 10.53, and Strongly Overvalued above 10.53. The current Forward P/FCF of 0.66 falls within the Historic Trend Line -Fairly Valued range.

Anavex Life Sciences Corp (AVXL) has a current Price-to-Book (P/B) ratio of 3.67. Compared to its 3-year average P/B ratio of 5.25 , the current P/B ratio is approximately -30.11% higher. Relative to its 5-year average P/B ratio of 6.78, the current P/B ratio is about -45.82% higher. Anavex Life Sciences Corp (AVXL) has a Forward Free Cash Flow (FCF) yield of approximately -10.87%. Compared to its 3-year average FCF yield of -5.29%, the current FCF yield is approximately 105.66% lower. Relative to its 5-year average FCF yield of -4.36% , the current FCF yield is about 149.30% lower.

3.67

P/B

Median3y

5.25

Median5y

6.78

-10.87

FCF Yield

Median3y

-5.29

Median5y

-4.36

Competitors Valuation Multiple

The average P/S ratio for AVXL's competitors is 61.53, providing a benchmark for relative valuation. Anavex Life Sciences Corp Corp (AVXL) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of AVXL increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of AVXL in the past 1 year is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is Anavex Life Sciences Corp (AVXL) currently overvalued or undervalued?

What is Anavex Life Sciences Corp (AVXL) fair value?

AVXL's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Anavex Life Sciences Corp (AVXL) is between to according to relative valuation methord.

How does AVXL's valuation metrics compare to the industry average?

The average P/S ratio for AVXL's competitors is 61.53, providing a benchmark for relative valuation. Anavex Life Sciences Corp Corp (AVXL) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for Anavex Life Sciences Corp (AVXL) as of Dec 15 2025?

As of Dec 15 2025, Anavex Life Sciences Corp (AVXL) has a P/B ratio of 3.67. This indicates that the market values AVXL at 3.67 times its book value.

What is the current FCF Yield for Anavex Life Sciences Corp (AVXL) as of Dec 15 2025?

As of Dec 15 2025, Anavex Life Sciences Corp (AVXL) has a FCF Yield of -10.87%. This means that for every dollar of Anavex Life Sciences Corp’s market capitalization, the company generates -10.87 cents in free cash flow.

What is the current Forward P/E ratio for Anavex Life Sciences Corp (AVXL) as of Dec 15 2025?

As of Dec 15 2025, Anavex Life Sciences Corp (AVXL) has a Forward P/E ratio of -8.37. This means the market is willing to pay $-8.37 for every dollar of Anavex Life Sciences Corp’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Anavex Life Sciences Corp (AVXL) as of Dec 15 2025?

As of Dec 15 2025, Anavex Life Sciences Corp (AVXL) has a Forward P/S ratio of 0.00. This means the market is valuing AVXL at $0.00 for every dollar of expected revenue over the next 12 months.

AVXL Valuation